Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.

Time: 8:00 AM – 5:00 PM

Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States

Prices: USD 2699.00 – USD 5297.00

Speakers: Pete Gough, Head of Research, Nimble Therapeutics, Shelley Allen, Project Director II, Immuno-Pharmacology and Peptide Discovery, Abbvie, Annette Bak, Head of Advanced Drug Delivery, AstraZeneca, and more